Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Amount Raised
$200 Million
Round Type
Post-IPO Equity
Investors
Description
On October 15, 2026, Recursion Pharmaceuticals entered into an underwriting agreement to sell 61,540,000 shares of its Class A common stock at a price of $3.25 per share. The gross proceeds from this offering are expected to be approximately $200 million, before deductions. The offering is slated to close on October 16, 2026, pending customary closing conditions. This capital infusion will support Recursion's ongoing drug discovery efforts.
Fundz sees it the moment Recursion Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Recursion Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.